Noble Financial Brokers Boost Earnings Estimates for UNCY

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Stock analysts at Noble Financial increased their Q3 2026 earnings per share estimates for Unicycive Therapeutics in a research report issued on Tuesday, March 31st. Noble Financial analyst R. Leboyer now anticipates that the company will post earnings per share of $0.79 for the quarter, up from their previous forecast of $0.74. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.36).

A number of other analysts have also recently weighed in on the stock. Westpark Capital assumed coverage on shares of Unicycive Therapeutics in a research note on Thursday, February 19th. They issued a “buy” rating on the stock. Guggenheim restated a “buy” rating on shares of Unicycive Therapeutics in a research note on Tuesday, December 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Unicycive Therapeutics has an average rating of “Moderate Buy” and an average price target of $34.33.

Unicycive Therapeutics Stock Performance

NASDAQ:UNCY opened at $6.58 on Wednesday. The company has a 50-day moving average of $6.66 and a 200-day moving average of $5.77. The company has a market capitalization of $141.40 million, a price-to-earnings ratio of -3.03 and a beta of 1.82. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $11.00.

Institutional Investors Weigh In On Unicycive Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Lazard Asset Management LLC bought a new stake in shares of Unicycive Therapeutics in the 2nd quarter worth about $55,000. JPMorgan Chase & Co. lifted its holdings in Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after purchasing an additional 21,525 shares during the last quarter. Quadrature Capital Ltd acquired a new position in Unicycive Therapeutics in the fourth quarter valued at about $226,000. Citadel Advisors LLC acquired a new position in Unicycive Therapeutics in the third quarter valued at about $182,000. Finally, State Street Corp grew its stake in Unicycive Therapeutics by 19.0% during the fourth quarter. State Street Corp now owns 65,227 shares of the company’s stock worth $376,000 after buying an additional 10,400 shares during the last quarter. Institutional investors and hedge funds own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.